type 2 diabetes
Conditions
Interventions
sitagliptin (50mg/day)
sitagliptin (50mg/day)
Sponsors
Department of internal medicine, Kobe University Graduate School of medicine Division of Diabetes, Metabolism and Endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.capable to be inserted catheters at three different site at both arms 2.capable to drink a bottle of liquid solution that corresponds to 75g glucose 3.capable to take a tablet of DPP-4 inhibitor
Exclusion criteria
Exclusion criteria: 1.Patients with type 2 diabetes used either alpha-glucosidase inhibitors nor any insulin products 2.Patients who had allergy to DPP-4 inhibitor 3.Patients who had insulin allergy 4.type 1 diabetes 5.pancreatic diabetes 6.Patients who had anti-insulin antibodies 7.Serious liver or renal diseases 8.Other conditions precluding participation as judged by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in glycemic control (1 week after initiation of DPP-4 inhibitor therapy) (FPG, AUC PG during breakfast, 1,5-AG) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Change in insulin secretion (1 week after initiation of DPP-4 inhibitor therapy) (FIRI, Proinsulin/insulin ratio, HOMA-b, AUC IRI during breakfast) 2.Change in insulin sensitivity (1 week after initiation of DPP-4 inhibitor therapy) (HOMA-R) 3.Change in glucagon secretion (1 week after initiation of DPP-4 inhibitor therapy) ( FIRG, AUC IRG during breakfast | — |
Countries
Japan
Contacts
Public ContactKazuhiko Sakaguchi
Department of internal medicine, Kobe University Graduate School of medicine Division of Diabetes, Metabolism and Endocrinology
Outcome results
None listed